Phase 2 Study Evaluating the Efficacy,Safety,Tolerability and PK of siG12D-LODER in the Treatment of Patients With Unresectable LAPC When Used in Conjunction With Standard Chemotherapy (Gemcitabine+Nab-Paclitaxel) Versus Chemotherapy Alone
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Antisense K-ras RNA gene therapy (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms PROTACT
- Sponsors Silenseed
- 14 Nov 2017 Planned primary completion date changed from 1 Feb 2019 to 1 Nov 2019.
- 14 Nov 2017 Planned initiation date changed from 1 Feb 2017 to 1 Nov 2017.
- 18 Oct 2016 Planned number of patients changed from 124 to 80.